Skip to main content

Table 1 Patient characteristics (n = 14)

From: Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

Baseline characteristics

 Gleason score, n (%)

  ≤7

1 (7)

  8

6 (43)

  9

6 (43)

  10

1 (7)

 Prior local treatment, n (%)

3 (21)

  Radical prostatectomy, n

1

  Radical radiation therapy, n

2

Patient characteristics at initiation of enzalutamide

 Median age, years (range)

78 (50–88)

 Median time from CRPC to initiation of enzalutamide, mo (range)

5.1 (1.3–75.4)

 ECOG PS, n (%)

  0

5 (36)

  1

6 (43)

  2

3 (21)

  ≥3

0

 Number of previous vintage hormone manipulations, median (range)

3 (2–7)

 Metastatic site, n (%)

  Bone

13 (100)

   EOD1

1 (7)

   EOD2

7 (50)

   EOD3

6 (43)

   EOD4

0

  Lymph node

6 (43)

  Lung

1 (7)

  Liver

1 (7)

 PSA (ng/ml), median (range)

89.9 (22.4–445.6)

 Hemoglobin (g/l), median (range)

11.4 (9.7–14.0)

 LDH (U/l), median (range)

254 (173–2028)

 ALP (U/l), median (range)

205 (99–1303)

Patient characteristics at time of initiation of abiraterone acetate

 Median time from enzalutamide discontinuation to initiation of abiraterone acetate, day (range)

1 (1–69)

 ECOG PS, n (%)

  0

3 (21)

  1

5 (36)

  2

6 (43)

  ≥3

0

 PSA (ng/ml), median (range)

38.0 (8.6–572.1)

 Hemoglobin (g/l), median (range)

11.8 (9.2–14.0)

 LDH (U/l), median (range)

202 (143–960)

 ALP (U/l), median (range)

316 (117–717)